Get a glimpse into our company and investor data—powered by the PitchBook Platform
M&ALATEST DEAL TYPE
$1.4BLATEST DEAL AMOUNT
Developer and marketer of novel, small molecule drugs for the treatment of cardiovascular diseases. The company's major products were Ranexa (ranolazine extended-release tablets) and Lexiscan (regadenoson).